Paragon Capital Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,839 shares of the company’s stock after selling 128 shares during the quarter. Johnson & Johnson comprises about 4.4% of Paragon Capital Management LLC’s holdings, making the stock its 8th biggest holding. Paragon Capital Management LLC’s holdings in Johnson & Johnson were worth $7,038,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after purchasing an additional 2,815,655 shares during the last quarter. State Street Corp increased its position in Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after buying an additional 803,013 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after acquiring an additional 805,831 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after acquiring an additional 328,297 shares during the period. Finally, California Public Employees Retirement System raised its position in Johnson & Johnson by 2.7% in the 3rd quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock valued at $1,919,726,000 after purchasing an additional 310,473 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Analyst Ratings Changes
JNJ has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. StockNews.com began coverage on Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Atlantic Securities decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Raymond James dropped their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. Finally, UBS Group initiated coverage on Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target for the company. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.
Insider Buying and Selling
Johnson & Johnson Stock Down 0.1 %
JNJ stock opened at $160.78 on Friday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The company has a market cap of $417.82 billion, a P/E ratio of 33.64, a P/E/G ratio of 2.77 and a beta of 0.53. The company’s 50-day moving average price is $159.10 and its 200 day moving average price is $166.76.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter in the prior year, the firm posted $2.67 EPS. The company’s revenue was up 5.6% compared to the same quarter last year. On average, research analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.96%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
- Oracle Stock Climbs For Third Month, Still In Buy Range
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
